-+ 0.00%
-+ 0.00%
-+ 0.00%

LLY.US (LLY.US) Class 1 New Drug Launches New Phase III Clinical Trial in China

Zhitongcaijing·08/17/2026 12:57:04
Listen to the news

The Zhitong Finance App learned that on August 17, the official website of the drug clinical trial registration and information disclosure platform showed that LY.US (LLY.US) registered a phase III clinical study of Brenipatide injections in adults with depression. According to the Insight database, Brenipatide is the world's first GLP-1 product to initiate phase III clinical trials for depression.

pictures

Screenshot source: Official website of the Drug Clinical Trial Registration and Information Disclosure Platform

Brenipatide is a GLP1R/GIPR dual agonist under development. It is also Lilly's second new GLP-1/GIP dual-target drug after tiverpotide. The highest progress in the world is in Phase III, and has not yet been approved for marketing. In addition to depression, Eli Lilly has initiated 2 Brenipatide Phase III studies on alcohol use disorders. In addition to this, Eli Lilly is also expanding other indications, including bipolar disorder, asthma, nicotine dependence, schizophrenia, irritable bowel syndrome with diarrhea, irritable bowel syndrome, chronic obstructive pulmonary disease, etc.